



UNICHEM
LABORATORIES LTD.

September 23, 2022

To,

The Manager – Department of
Corporate Services
Bombay Stock Exchange Limited
P. J. Towers
Dalal Street, Fort
Mumbai – 400001

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C-1, Block G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400051

Dear Sir/Madam,

SUB: Intimation and disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (“Listing Regulations”)

This is to inform you that pursuant to our intimation and disclosure dated May 10, 2022 under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the sale of 19.97% equity shares of the Company in Optimus Drugs Private Limited ("**Optimus**") to Sekhmet Pharmaventures Private Limited ("**Purchaser**"), was completed on September 22, 2022 and we have received payment towards completion of sale of first tranche, the details of which is mentioned herein below.

This intimation is given under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

In terms of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9 September 2015. Please refer to Annexure I attach herewith for further details in relation to the change in the shareholding from the last disclosure made.

Kindly take the above on record and oblige.

Thanking you.

Yours faithfully

For **Unichem Laboratories Limited**



Pradeep Bhandari

Head – Legal & Company Secretary



Annexure I – Part A 1 (ii)(b) Change in the shareholding from the last disclosure made by the Company: Optimus Drugs Private Limited

S. No.	Details required	Information about such event
a)	Name of the target entity, details in brief such as size, turnover etc.	Sale of equity shares held by the Company in Optimus Drugs Private Limited (" Optimus ") to Sekhmet Pharmaventures Private Limited. Total turnover of Optimus (unaudited): Rs. INR 1130 crores (21-22)
b)	Whether the acquisition /sale would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
c)	industry to which the entity being sold/ acquired belongs;	Active pharmaceutical ingredients (" APIs ") and intermediates
d)	objects and effects of acquisition /sale (including but not limited to, disclosure of reasons for acquisition /sale of the target entity, if its business is outside the main line of business of the listed entity);	Liquidation of strategic investment by the Company.
e)	brief details of any governmental or regulatory approvals required for the acquisition;	Approval from the Competition Commission of India has been received.



UNICHEM LABORATORIES LTD.

f)	The indicative time period for completion of the sale/ acquisition ;	First tranche completed on 22 September 2022. For the second tranche: after satisfaction of necessary conditions precedent as mutually agreed under the share purchase agreement.
g)	nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration
h)	cost of sale/ acquisition or the price at which the shares are sold/ acquired ;	For the first tranche - INR 270,98,99,010 For the second tranche- for a price to be determined as per the said share purchase agreement after satisfaction of necessary conditions precedent.
i)	percentage of shareholding / control sold/ acquired and / or number of shares sold/ acquired ;	(i) sold 19.97% equity shares on a fully diluted basis in the first tranche; and (ii) sale of remaining 0.02% equity shares in the second tranche.
j)	brief background about the entity sold/ acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Incorporated on December 2, 2003, Optimus is engaged in the business of researching, developing, manufacturing, marketing, and distribution of active pharmaceutical ingredients and intermediates. Optimus's turnover was Rs 528 Crores (audited) in 2019-20, Rs. 1019 Crores (audited) in 2020-21 and Rs. 1130 Crore (unaudited) in 2021-22.